BridgeMD
Efficacy and safety of two moisturising creams for maintenance treatment of atopic dermatitis
EU CTIS ID: 2025-521620-29-01
What this study is testing
To demonstrate superiority in time to relapse of eczema with moisturisers Oviderm cream and Urea/propylene glycol cream, respectively, as compared to non-treatment
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • The patient has given their written consent to participate in the study
- • Age ≥ 18 years
- • Patients with known AD or diagnosed with AD according to the Williams criteria [1] with visible atopic lesions on arms and/or legs. Two lesions on left respective right side with a size of 2 x 2 cm to 10 x 10 cm should be available, i.e., study areas. The largest lesion should not be more than 50% larger than the smallest lesion in length and width, i.e., the length of the largest selected lesion ≤ 1.5× the length of the smallest and the width of the largest selected lesion ≤ 1.5× width of the smallest lesion
- • Moderate to severe form of AD, IGA ≥ 3 [2], a mEASI score on the defined study areas of ≥ 4 and with a difference between left study area to right study area of ≤ 1 and which, in the opinion of the Investigator, can achieve complete clearance with a class III corticosteroid treatment for approximately 4 weeks
You likely can't join if
- • Eczema exclusively on the hands
- • Patients assessed by the Investigator to have mild atopic dermatitis
- • Patients treated for AD with systemic drugs, topical corticosteroids class IV and light treatment during the last 3 months
- • Any concomitant medications that, in the opinion of the Investigator, could affect the study outcome
- • Known sensitivity or allergy to any of the study products
- • Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (e.g., compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments or procedures
See the full eligibility criteria
- • The patient has given their written consent to participate in the study
- • Age ≥ 18 years
- • Patients with known AD or diagnosed with AD according to the Williams criteria [1] with visible atopic lesions on arms and/or legs. Two lesions on left respective right side with a size of 2 x 2 cm to 10 x 10 cm should be available, i.e., study areas. The largest lesion should not be more than 50% larger than the smallest lesion in length and width, i.e., the length of the largest selected lesion ≤ 1.5× the length of the smallest and the width of the largest selected lesion ≤ 1.5× width of the smallest lesion
- • Moderate to severe form of AD, IGA ≥ 3 [2], a mEASI score on the defined study areas of ≥ 4 and with a difference between left study area to right study area of ≤ 1 and which, in the opinion of the Investigator, can achieve complete clearance with a class III corticosteroid treatment for approximately 4 weeks
- • Eczema exclusively on the hands
- • Patients assessed by the Investigator to have mild atopic dermatitis
- • Patients treated for AD with systemic drugs, topical corticosteroids class IV and light treatment during the last 3 months
- • Any concomitant medications that, in the opinion of the Investigator, could affect the study outcome
- • Known sensitivity or allergy to any of the study products
- • Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the participant (e.g., compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments or procedures
- • Patients assessed by the Investigator to have poor compliance
- • Patients assessed by the Investigator to have difficulty reading and understanding the local language
- • Patients who are pregnant, breast feeding or planning to become pregnant during study participation
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.